PHAXIAM Therapeutics S.A. Stock Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.915 EUR | -1.19% | 0.00% | -36.63% |
Sales 2023 | - | Sales 2024 * | 1.05M 1.12M | Capitalization | 17.71M 18.84M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.47M | Net income 2024 * | - 0 | EV / Sales 2023 | - |
Net Debt 2023 * | 3.3M 3.51M | Net Debt 2024 * | 450K 479K | EV / Sales 2024 * | 17.3 x |
P/E ratio 2023 * |
-0.68
x | P/E ratio 2024 * |
-2.07
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 92.14% |
Latest transcript on PHAXIAM Therapeutics S.A.
1 week | -0.17% | ||
Current month | -2.18% | ||
1 month | +0.69% | ||
3 months | -30.68% | ||
6 months | -34.49% | ||
Current year | -36.63% |
Managers | Title | Age | Since |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 2.915 | -1.19% | 1,337 |
24-04-17 | 2.95 | +0.34% | 2,729 |
24-04-16 | 2.94 | +0.17% | 3,723 |
24-04-15 | 2.935 | +0.17% | 3,460 |
24-04-12 | 2.93 | +0.34% | 9,489 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock